 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 2703 | 回復(fù): 4 | |||||||
[交流]
諾華上海研發(fā)中心招聘
|
China Novartis Institutes for BioMedical Research Co., Ltd. (CNIBR) has some job vacancies as below. If you have interested in these jobs, please send your resume with no hesitation cause we'll provide you more chance to promote yourself in your field. Research Scientist-Liver Disease For more details, please click our career website: http://careers.novartis.com.cn/vacancies.html To apply this position, please send your resume to sarah.qi@novartis.com When you send your resume to sarah.qi@novartis.com, please notice you know this position information via 小木蟲BBS 諾華（中國）生物醫(yī)學(xué)研究有限公司是諾華全球研發(fā)組織――諾華生物醫(yī)學(xué)研究所（NIBR）的第八個研究基地。我們位于中國上海市張江高科技園區(qū)，將成為諾華在亞洲的主要研究中心，以及除在歐美的研究中心外的最主要的研究中心。我們的研究和探索開發(fā)活動的重點是發(fā)現(xiàn)并開發(fā)創(chuàng)新療法，用于治療在亞洲遠(yuǎn)未達(dá)到醫(yī)藥需求的疾病。我們與從不同之處在于將專注現(xiàn)代藥物的發(fā)現(xiàn)和開發(fā)方法的研究。最初階段，研發(fā)工作將專注在引起中國地方性癌癥的感染原因。我們還將開展臨床試驗，進(jìn)行安全性研究，生物標(biāo)志物和檢測分析，表達(dá)譜、生物分析以及轉(zhuǎn)化醫(yī)學(xué)的研究。 隨著公司業(yè)務(wù)的迅速擴(kuò)展，我們熱忱歡迎您的加入。同時我們將提供具有競爭力的薪酬福利待遇以及良好的培訓(xùn)發(fā)展機(jī)會。 NIBR Shanghai NIBR Shanghai is an integrated research center that is part of the Novartis global research and development network. The establishment of this strategic site is a commitment by Novartis to conduct cutting-edge pharmaceutical research in China. Research activities at NIBR Shanghai focus on addressing urgent medical needs in China, particularly infectious causes of cancer endemic to the region. The center also established programs in epigenetics, biomarker development, drug metabolism and preclinical safety to support NIBR local and global R&D projects.Research at NIBR Shanghai is currently focused on discovering new therapies for infectious causes of cancer, such as liver cancer caused by HBV or HCV hepatitis. As the diseases are highly prevalent in the region, some one-third of the 400 million people infected with the hepatitis B virus are in China, with estimates that 300,000 people die from liver cancer in the mainland each year. A Growing and Dynamic Organization China Novartis Institutes for BioMedical Research Co., Ltd. (CNIBR), the legal entity for NIBR Research Center in Shanghai was launched in November 2006 and the start-up Research facilities opened in April 2007. Today, NIBR Shanghai has grown to an organization of about 260 associates including nearly 200 scientists. The research teams are comprised of both returnee scientists from abroad (about 20% of total scientists), and graduates from top tier universities, medical centers, and research institutes in China. Currently the center operates in an office building and two lab facilities in the Zhangjiang Hi-Tech Park. In the same area, the new Novartis Shanghai Campus is under design and construction. The first phase of the project will be completed by the end of 2014. |
回復(fù)此樓» 猜你喜歡
286分人工智能專業(yè)請求調(diào)劑愿意跨考！
已經(jīng)有5人回復(fù)
-
279求調(diào)劑
已經(jīng)有3人回復(fù)
-
336求調(diào)劑
已經(jīng)有3人回復(fù)
-
286求調(diào)劑
已經(jīng)有3人回復(fù)
-
一志愿華中科技大學(xué)071000，求調(diào)劑
已經(jīng)有3人回復(fù)
-
279分求調(diào)劑 一志愿211
已經(jīng)有14人回復(fù)
-
332求調(diào)劑
已經(jīng)有3人回復(fù)
-
0856材料專碩353求調(diào)劑
已經(jīng)有3人回復(fù)
-
材料學(xué)學(xué)碩080502 337求調(diào)劑-一志愿華中科技大學(xué)
已經(jīng)有5人回復(fù)
-
085601調(diào)劑 358分
已經(jīng)有4人回復(fù)
|
Research Scientist-Liver Disease Job Description China Novartis Institutes for Biomedical Research Co. Ltd (CNIBR) is currently seeking to fill a research scientist position in Biology Department. Self-motivated scientist with strong interest in drug discovery studies in liver diseases, esp in liver fibrosis/cirrhosis is welcome. The candidate will apply cell biology, molecular biology and biochemistry expertise on drug target validation, assay development, novel target identification as well as mechanistic studies. The candidate is expected to have the ability to handle multiple projects simultaneously and works in a fast-paced environment. Oral and written reports in English are also required regularly. Minimum requirements Candidates should hold an M.S./Ph.D. in Cell Biology, Molecular Biology, Developmental Biology or related field and have at least two years of relevant experience. Strong background and hands-on experience in liver diseases is preferred. The successful candidate is expected to have strong work ethic, excellent oral and written communication in English, and ability to function in an interdisciplinary team setting are essential. |
2樓2013-10-10 17:14:14
3樓2013-10-10 22:21:13
4樓2013-10-12 10:07:03
5樓2013-10-12 10:17:15
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 saliand 的主題更新
| 5 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 0856材料專碩353求調(diào)劑 +3 | NIFFFfff 2026-03-20 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 313求調(diào)劑 +3 | 肆叁貳壹22 2026-03-19 | 3/150 |
|
|
|
[考研] 301求調(diào)劑 +10 | yy要上岸呀 2026-03-17 | 10/500 |
|
|
|
[考研] 085700資源與環(huán)境308求調(diào)劑 +12 | 墨墨漠 2026-03-18 | 13/650 |
|
|
|
[考研] 材料 336 求調(diào)劑 +3 | An@. 2026-03-18 | 4/200 |
|
|
|
[考研] 華東師范大學(xué)-071000生物學(xué)-293分-求調(diào)劑 +3 | 研究生何瑤明 2026-03-18 | 3/150 |
|
|
|
[考研] 一志愿 西北大學(xué) ，070300化學(xué)學(xué)碩，總分287，雙非一本，求調(diào)劑。 +3 | 晨昏線與星海 2026-03-18 | 3/150 |
|
|
|
[考研] 一志愿重慶大學(xué)085700資源與環(huán)境專碩，總分308求調(diào)劑 +3 | 墨墨漠 2026-03-18 | 3/150 |
|
|
|
[考研] 317求調(diào)劑 +8 | 申子申申 2026-03-19 | 13/650 |
|
|
|
[考研] 308求調(diào)劑 +3 | 阿姐阿姐家啊 2026-03-18 | 3/150 |
|
|
|
[考研]
 295復(fù)試調(diào)劑
+8
|
簡木ChuFront 2026-03-19 | 8/400 |
|
|
|
[考研] 260求調(diào)劑 +3 | 朱芷琳 2026-03-20 | 3/150 |
|
|
|
[論文投稿]
申請回稿延期一個月，編輯同意了。但系統(tǒng)上的時間沒變，給編輯又寫郵件了，沒回復(fù)
 10+3
|
wangf9518 2026-03-17 | 4/200 |
|
|
|
[考研] 286求調(diào)劑 +6 | lemonzzn 2026-03-16 | 10/500 |
|
|
|
[考研] 一志愿福大288有機(jī)化學(xué)，求調(diào)劑 +3 | 小木蟲200408204 2026-03-18 | 3/150 |
|
|
|
[考研] 一志愿985，本科211，0817化學(xué)工程與技術(shù)319求調(diào)劑 +10 | Liwangman 2026-03-15 | 10/500 |
|
|
|
[考研] 考研求調(diào)劑 +3 | 橘頌. 2026-03-17 | 4/200 |
|
|
|
[考研] 326求調(diào)劑 +5 | 上岸的小葡 2026-03-15 | 6/300 |
|
|
|
[考研] 材料專碩326求調(diào)劑 +6 | 墨煜姒莘 2026-03-15 | 7/350 |
|
|
|
[考研] 085601材料工程315分求調(diào)劑 +3 | yang_0104 2026-03-15 | 3/150 |
|